Recently, several publications have pointed out that intestinal dysbiosis is linked not only to the pathogenesis of intestinal disorders but also to a series of extra-intestinal diseases, such as non-alcoholic fatty liver disease (NAFLD) and the metabolic syndrome (MetS). The term “metabolic syndrome” does not refer to a single disease, but to a set of risk factors linked to conditions that increase the chance to develop cardiometabolic diseases.
Manipulation of the intestinal microbiota could be a promising weapon for the prevention and management of metabolic diseases and, for this reason, nutritional strategies aimed at restoring eubiosis must be approached from a global perspective. To address this problem, this study reports the effects of the ingredient SynBalance® MetSyn, winner of the NutraIngredients Awards Europe 2021 for the “weight control” category, in a randomized, double-blind, controlled clinical trial with placebo.
Read the full article from L’Integratore Nutrizionale